<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03288883</url>
  </required_header>
  <id_info>
    <org_study_id>RCTGSM</org_study_id>
    <nct_id>NCT03288883</nct_id>
  </id_info>
  <brief_title>RCT of Laser Therapy for GSM</brief_title>
  <official_title>Fractional Microablative CO2-laser Versus Photothermal Non-ablative Erbium:YAG-laser for the Management of Genitourinary Syndrome of Menopause: A Non-inferiority, Single-blind Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexandra Hospital, Athens, Greece</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College Hospital NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to assess whether the CO2-laser results in superior&#xD;
      alleviation of GSM symptoms compare to Er:YAG-laser. Specifically, we will compare objective&#xD;
      and subjective measurements of symptoms and clinical signs of GSM, between groups of&#xD;
      postmenopausal women with GSM receiving treatment with CO2-laser or Er:YAG-laser.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Genitourinary Syndrome of Menopause (GSM) is the new terminology for &quot;vulvovaginal (VVA)&quot;.&#xD;
      Although women may present with some or all of the clinical signs and symptoms, the most&#xD;
      common symptom of VVA/GSM is vaginal dryness. Vaginal dryness appears early at menopause with&#xD;
      a subsequent increase of prevalence as postmenopausal years' progresses and is associated&#xD;
      with rising occurrence of lower urinary tract symptoms (LUTS).&#xD;
&#xD;
      The therapeutic management of GSM includes lubricants and moisturizers as a first line&#xD;
      therapy and low-dose vaginal estrogens as a second one, especially for women with a history&#xD;
      of estrogen dependent cancer. However, lubricants and moisturizers can only be used for&#xD;
      symptoms relief during sexual intercourse. They do not restore the local pathophysiology and&#xD;
      they are inefficacious when LUTS are present. However, the quality of evidence is low or&#xD;
      very-low when estrogens efficacy is compared to placebo, while the risk to the endometrial&#xD;
      thickness with sustained vaginal estrogen use is not clear.&#xD;
&#xD;
      Recently, intravaginal laser therapy has been proposed for the management of GSM. There are&#xD;
      currently two lasers available. All available studies consistently suggest that both lasers&#xD;
      (CO2-laser and Er:YAG-laser) are safe and have a high efficacy on alleviating vaginal dryness&#xD;
      and dyspareunia, as well as restoring the local pathophysiology. Additionally, data regarding&#xD;
      CO2-laser indicate LUTS improvement, as well as sexual function-satisfaction and quality of&#xD;
      women's life. Relevant published data are not available for the Er:YAG-laser. Moreover, there&#xD;
      is lack of studies comparing the 2 laser-technologies for the management of postmenopausal&#xD;
      women with GSM.&#xD;
&#xD;
      The aim of the current study is to assess whether the CO2-laser results in superior&#xD;
      alleviation of GSM symptoms compare to Er:YAG-laser. Specifically, we will compare objective&#xD;
      and subjective measurements of symptoms and clinical signs of GSM, between groups of&#xD;
      postmenopausal women with GSM receiving treatment with CO2-laser or Er:YAG-laser.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">February 11, 2021</completion_date>
  <primary_completion_date type="Actual">February 11, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dryness - 10cm visual analogue scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyspareunia- 10cm visual analogue scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Itching- 10cm visual analogue scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Burning- 10cm visual analogue scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dysuria- 10cm visual analogue scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency- 10cm visual analogue scale,</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urgency-10cm visual analogue scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary incontinence- 10cm visual analogue scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall sexual satisfaction- Female sexual function index</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency- 3 day voiding diary</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urgency- 3 day voiding diary,</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary incontinence- 3 day voiding diary</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall sexual satisfaction- 10cm visual analogue scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall sexual satisfaction- frequency of sexual intercourse,</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life- patients global impression of improvement questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life- day to day impact of vaginal ageing questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life- kings health questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global impression of improvement- day to day impact of vaginal ageing questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global impression of improvement- patients global impression of improvement questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global impression of improvement- kings health questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal health index score- 5 components, elasticity, epithelial integrity, pH, moisture and fluid volume</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal maturation value- vaginal smear stained with papanicolaou technique and VMI value is evaluated by defining the percentage of superficial, intermediate and paranasal epithelial cells on smear.</measure>
    <time_frame>1 year</time_frame>
    <description>VMV = ((1x%superficial)+(0.5x%intermediate)+0xparabasal))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Genitourinary Syndrome of Menopause</condition>
  <arm_group>
    <arm_group_label>Fractional Microablative CO2-laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Photothermal Non-ablative Erbium:YAG-laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photothermal Non-ablative Erbium:YAG-laser</intervention_name>
    <description>Laser treatment of the vagina for GSM</description>
    <arm_group_label>Photothermal Non-ablative Erbium:YAG-laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional Microablative CO2-laser</intervention_name>
    <description>Laser treatment of the vagina for GSM</description>
    <arm_group_label>Fractional Microablative CO2-laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Dryness and dyspareunia with moderate to severe intensity&#xD;
&#xD;
          2. Vaginal Health Index &lt;15&#xD;
&#xD;
          3. Absence of menstruation for at least 12 months&#xD;
&#xD;
          4. Recent Negative Pap-smear test (For women over 65 years old a negative pap smear test&#xD;
             up to the age of 65).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not willing to abstain from vaginal intercourse for one week following the&#xD;
             laser-therapy&#xD;
&#xD;
          2. Use of hormonal therapy within 6 months prior to study inclusion (systemic or local)&#xD;
&#xD;
          3. Acute urinary tract infections (UTIs)&#xD;
&#xD;
          4. History of a genital fistula, a thin recto-vaginal septum as determined by the&#xD;
             investigator or history of a fourth-degree laceration during screening physical exam&#xD;
             (e.g., perineal body)&#xD;
&#xD;
          5. Active sexually transmitted disease upon vaginal exam (as determined by the&#xD;
             investigator) that precludes treatment or any other vaginal infection&#xD;
&#xD;
          6. Active or history of genital herpes&#xD;
&#xD;
          7. Prolapse stages &gt; II (according to the POP-Q system)&#xD;
&#xD;
          8. History of radiotherapy for cervical or uterine cancer&#xD;
&#xD;
          9. Medical condition that may interfere with participants' compliance to the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urogynaecology Department, King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

